vs
Side-by-side financial comparison of DuPont (DD) and Incyte (INCY). Click either name above to swap in a different company.
DuPont is the larger business by last-quarter revenue ($1.7B vs $1.3B, roughly 1.3× Incyte). Incyte runs the higher net margin — 23.8% vs 9.8%, a 14.1% gap on every dollar of revenue. On growth, Incyte posted the faster year-over-year revenue change (20.9% vs 4.0%). Over the past eight quarters, Incyte's revenue compounded faster (10.4% CAGR vs -27.2%).
DuPont de Nemours, Inc., commonly shortened to DuPont, is an American multinational chemical company first formed in 1802 by French-American chemist and industrialist Éleuthère Irénée du Pont de Nemours. The company played a major role in the development of the U.S. state of Delaware and first arose as a major supplier of gunpowder.
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
DD vs INCY — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.7B | $1.3B |
| Net Profit | $164.0M | $303.3M |
| Gross Margin | 35.8% | — |
| Operating Margin | — | 23.7% |
| Net Margin | 9.8% | 23.8% |
| Revenue YoY | 4.0% | 20.9% |
| Net Profit YoY | — | 91.7% |
| EPS (diluted) | $0.36 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.7B | $1.3B | ||
| Q4 25 | $-2.5B | $1.5B | ||
| Q3 25 | $3.1B | $1.4B | ||
| Q2 25 | $3.3B | $1.2B | ||
| Q1 25 | $3.1B | $1.1B | ||
| Q4 24 | $3.1B | $1.2B | ||
| Q3 24 | $3.2B | $1.1B | ||
| Q2 24 | $3.2B | $1.0B |
| Q1 26 | $164.0M | $303.3M | ||
| Q4 25 | $-126.0M | $299.3M | ||
| Q3 25 | $-123.0M | $424.2M | ||
| Q2 25 | $59.0M | $405.0M | ||
| Q1 25 | $-589.0M | $158.2M | ||
| Q4 24 | $-118.0M | $201.2M | ||
| Q3 24 | $454.0M | $106.5M | ||
| Q2 24 | $178.0M | $-444.6M |
| Q1 26 | 35.8% | — | ||
| Q4 25 | — | 92.0% | ||
| Q3 25 | 38.9% | 92.8% | ||
| Q2 25 | 37.3% | 93.5% | ||
| Q1 25 | 37.4% | 93.0% | ||
| Q4 24 | 36.4% | 92.5% | ||
| Q3 24 | 37.4% | 92.4% | ||
| Q2 24 | 37.1% | 92.7% |
| Q1 26 | — | 23.7% | ||
| Q4 25 | — | 22.3% | ||
| Q3 25 | 10.6% | 32.5% | ||
| Q2 25 | 9.4% | 43.6% | ||
| Q1 25 | -14.0% | 19.5% | ||
| Q4 24 | 1.4% | 25.6% | ||
| Q3 24 | 18.4% | 12.8% | ||
| Q2 24 | 9.3% | -45.8% |
| Q1 26 | 9.8% | 23.8% | ||
| Q4 25 | 4.9% | 19.9% | ||
| Q3 25 | -4.0% | 31.1% | ||
| Q2 25 | 1.8% | 33.3% | ||
| Q1 25 | -19.2% | 15.0% | ||
| Q4 24 | -3.8% | 17.1% | ||
| Q3 24 | 14.2% | 9.4% | ||
| Q2 24 | 5.6% | -42.6% |
| Q1 26 | $0.36 | $1.47 | ||
| Q4 25 | $-0.30 | $1.46 | ||
| Q3 25 | $-0.29 | $2.11 | ||
| Q2 25 | $0.14 | $2.04 | ||
| Q1 25 | $-1.41 | $0.80 | ||
| Q4 24 | $-0.28 | $0.90 | ||
| Q3 24 | $1.08 | $0.54 | ||
| Q2 24 | $0.42 | $-2.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $710.0M | — |
| Total DebtLower is stronger | $3.2B | — |
| Stockholders' EquityBook value | $14.2B | $5.6B |
| Total Assets | $21.4B | $7.3B |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $710.0M | — | ||
| Q4 25 | $715.0M | $3.1B | ||
| Q3 25 | $2.0B | $2.5B | ||
| Q2 25 | $1.8B | $2.0B | ||
| Q1 25 | $1.8B | $1.9B | ||
| Q4 24 | $1.9B | $1.7B | ||
| Q3 24 | $1.6B | $1.3B | ||
| Q2 24 | $1.5B | $987.3M |
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.1B | — | ||
| Q3 25 | $7.0B | — | ||
| Q2 25 | $5.3B | — | ||
| Q1 25 | $5.3B | — | ||
| Q4 24 | $5.3B | — | ||
| Q3 24 | $7.2B | — | ||
| Q2 24 | $7.2B | — |
| Q1 26 | $14.2B | $5.6B | ||
| Q4 25 | $13.9B | $5.2B | ||
| Q3 25 | $22.9B | $4.7B | ||
| Q2 25 | $23.1B | $4.2B | ||
| Q1 25 | $22.8B | $3.7B | ||
| Q4 24 | $23.4B | $3.4B | ||
| Q3 24 | $24.2B | $3.2B | ||
| Q2 24 | $23.3B | $3.0B |
| Q1 26 | $21.4B | $7.3B | ||
| Q4 25 | $21.6B | $7.0B | ||
| Q3 25 | $38.0B | $6.3B | ||
| Q2 25 | $36.6B | $5.8B | ||
| Q1 25 | $36.0B | $5.7B | ||
| Q4 24 | $36.6B | $5.4B | ||
| Q3 24 | $37.5B | $5.0B | ||
| Q2 24 | $36.6B | $4.7B |
| Q1 26 | 0.22× | — | ||
| Q4 25 | 0.23× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.23× | — | ||
| Q4 24 | 0.23× | — | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 0.31× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
